---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-036822"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:18:32.121864+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology sells royalty rights to Novartis for $8M upfront cash

## Summary
- One-time $8M payment from Novartis for rights to Beovu and another asset royalties.
- All prior royalties from Apexigen and Pyxis Oncology are free from reclaim.
- Non-dilutive capital to support lead ADC asset PYX-201 development.
- Pyxis retains rights to three other antibodies from Apexigen licensees.
- $8M payment to be recorded in Q1 2024.

## SEC filing metadata
- accession: 0000950170-24-036822
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017024036822/0000950170-24-036822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017024036822/pyxs-20240327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-036822
- JSON: https://secwatch.observer/filing/0000950170-24-036822.json
- Plain text: https://secwatch.observer/filing/0000950170-24-036822.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.